You know, earlier this week we were at a benefits conference, and what the conversation really centered around sort of for this year was, so this idea that, you know, your average employee benefits portfolio is about 28 different point solutions today, and that the conversation is really around in the current budgetary environment with healthcare costs continuing to rise at accelerating rates, is more of a consolidation, looking to see where there are duplicate solutions and then optimizing for outcomes
If anemia and symptoms are severe, early labs (e.g
Stronger effect than Selank but with slower onset
This is an independent research guide
Both Danuglipron and Lotiglipron ultimately failed due to liver-related concerns, despite strong oral bioavailability and early promise
Instead of being broken down in the gut, the glutathione remains intact, providing a more reliable way to support your levels than diet or standard pills alone